Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
Press Release|Articles|August 22, 2023

Willow Biosciences Announces Collaboration with Biopharma Company

Author(s)Jill Murphy

The collaboration partner for Willow is focused on more sustainable methods to manufacture intermediates and APIs at reduced cost and less waste, in addition to looking for Willow’s expertise in developing and scaling key ingredients.

Willow Biosciences, a leading biotechnology company focused on revolutionizing sustainable, functional ingredients, announced a collaboration with a Nasdaq-listed biopharma company on Aug. 21, 2023 to develop new sustainable manufacturing routes to key intermediates and active pharmaceutical ingredients (APIs), according to a press release.

The collaboration partner for Willow is focused on more sustainable methods to manufacture intermediates and APIs at reduced cost and less waste, in addition to looking for Willow’s expertise in developing and scaling key ingredients. Further, the initial program plans to focus on the practicability of creating a biobased pathway and advance development toward implementation at commercial scale, which is expected to last approximately two months.

The partner’s name and other information are not being shared currently due to the competitive nature of the targeted ingredient applications, according to the press release.

“We are honored to have been selected by such a forward-thinking biopharmaceutical company to jointly explore innovative pathways toward the development of sustainably sourced intermediates and APIs,” said Dr. Chris Savile, Willow’s president & CEO, in a press release. “If successful, we believe that by leveraging biobased routes, these ingredients essential for human health can be made more broadly available while providing a solution for overseas supply chain issues that can increase cost and potentially create shortages.”

Source: Willow Bio


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.